1 terminated, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
Follow Costantine Albany: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy Rolapitant, Palonosetron, Olanzapine - Germ Cell Tumor | Phase 2 | Withdrawn | Costantine Albany | 2018-05-01 | 2019-05-22 | |
| OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone OGX-427, Abiraterone Acetate, Prednisone - Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer | Phase 2 | Terminated | Costantine Albany | 72 | 2012-12-01 | 2022-07-11 |
Neoplasms, Germ Cell and Embryonal (1) · Prostatic Neoplasms (1)
Abiraterone Acetate (1) · Dexamethasone (1) · Olanzapine (1) · Palonosetron (1) · Prednisone (1) · Steroids (1) · apatorsen (1) · rolapitant (1)
Canada (1) · United States (1)